Life Science Executive Partnering
Congress Sept 23-24, Forums Sept 22, 2026Hynes Convention Center, Boston, USA Peter JensenCEO / Founder at Chosa OncologySpeaker
Profile
Peter Buhl Jensen has 35 years of experience in clinical cancer therapy and as a serial entrepreneur. He is the founder/co-founder of Oncology Venture A/S, TopoTarget A/S which he also led as the CEO. He has also co-founded and CHOSA Oncology AB and Buhl Oncology ApS and has been key in the development and approval of the cancer drugs Savene® (EU approval 2006, FDA 2007) & Belinostat® (FDA approval 2014). Buhl Jensen was the Chief Oncologist and chief executive at the Oncology department at Rigshospitalet (2000-08), and Aalborg University Hospital (2010-11).
Agenda Sessions
Building a Winning Commercialization Strategy for First-in-Class Therapies
, 10:50amView Session